Literature DB >> 426964

Haemodynamic effects of sodium nitroprusside in 21 subjects with congestive heart failure.

S A Lukes, C A Romero, L Resnekov.   

Abstract

Twenty-one patients in severe congestive heart failure refractory to conventional medical management were treated with sodium nitroprusside on 22 occasions. On 14 occasions (responders) there was significant improvement in clinical and haemodynamic indices. On 8 occasions (non-responders) hypotension developed without haemodynamic improvement and nitroprusside treatment had to be abandoned. The initial mean arterial pressure and the capillary wedge pressure tended to be higher in the responders while the cardiac index tended to be higher in the non-responders. The systemic vascular resistance was higher in the responders than in the non-responders (2560 +/- 160 vs 1800 +/- 180 dynes s cm-5, P less than 0.001). All of the responders had systemic vascular resistance greater than 1900 dynes s cm-5, while only one of the non-responders had a systemic vascular resistance in this range. Thus, a variable response to vasodilator therapy for congestive cardiac failure is documented. The favourable response appears to be limited to patients with a high systemic vascular resistance.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 426964      PMCID: PMC486850          DOI: 10.1136/hrt.41.2.187

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  11 in total

Review 1.  Drug therapy. Sodium nitroprusside.

Authors:  R F Palmer; K C Lasseter
Journal:  N Engl J Med       Date:  1975-02-06       Impact factor: 91.245

2.  Improved left ventricular function during nitroprusside infusion in acute myocardial infarction.

Authors:  J A Franciosa; C J Limas; N H Guiha; E Rodriguera; J N Cohn
Journal:  Lancet       Date:  1972-03-25       Impact factor: 79.321

3.  Phentolamine for vasodilator treatment of severe heart-failure.

Authors:  P A Majid; B Sharma; S H Taylor
Journal:  Lancet       Date:  1971-10-02       Impact factor: 79.321

4.  Blood pressure and cardiac performance.

Authors:  J N Cohn
Journal:  Am J Med       Date:  1973-09       Impact factor: 4.965

5.  Beneficial effects of vasodilator agents in severe mitral regurgitation due to dysfunction of subvalvar apparatus.

Authors:  K Chatterjee; W W Parmley; H J Swan; G Berman; J Forrester; H S Marcus
Journal:  Circulation       Date:  1973-10       Impact factor: 29.690

6.  Treatment of refractory heart failure with infusion of nitroprusside.

Authors:  N H Guiha; J N Cohn; E Mikulic; J A Franciosa; C J Limas
Journal:  N Engl J Med       Date:  1974-09-19       Impact factor: 91.245

7.  Hemodynamic and metabolic responses to vasodilator therapy in acute myocardial infarction.

Authors:  K Chatterjee; W W Parmley; W Ganz; J Forrester; P Walinsky; C Crexells; H J Swan
Journal:  Circulation       Date:  1973-12       Impact factor: 29.690

8.  Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance.

Authors:  J N Cohn
Journal:  Circulation       Date:  1973-07       Impact factor: 29.690

9.  Circulatory effects of acute myocardial infarction as a rational basis for therapy.

Authors:  L Resnekov; H Lipp
Journal:  Ann Clin Res       Date:  1971-12

10.  Clinical use of sodium nitroprusside in chronic ischemic heart disease. Effects on peripheral vascular resistance and venous tone and on ventricular volume, pump and mechanical performance.

Authors:  R R Miller; L A Vismara; R Zelis; E A Amsterdam; D T Mason
Journal:  Circulation       Date:  1975-02       Impact factor: 29.690

View more
  2 in total

Review 1.  Intravenous vasodilator therapy in congestive heart failure.

Authors:  Kourosh Moazemi; Jatinder S Chana; Anna Marie Willard; Abraham G Kocheril
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

2.  Hemodynamic effects of sodium nitroprusside in patients with ventricular septal defect.

Authors:  R Subramanyam; R Tandon; S Shrivastava
Journal:  Eur J Pediatr       Date:  1982-07       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.